InvestSMART

Polynovo Limited (ASX:PNV)

ALERT: Price-sensitive ASX Announcement for PNV
Current share price for PNV : $0.905 -0.045 (-4.74%)+
Announcement
Release
23 Jul 2026 8:30AM
Price at Release
$0.950
Full Release
download
Summary
PolyNovo Limited reported a strong financial performance for FY26, with a notable 16.1% increase in group revenue to AUD 150 million, and a significant uptick in U.S. commercial sales. The company completed its new manufacturing facility and continued to recover costs from insurance after a fire at their R&D centre. They have expanded their U.S. sales team and are preparing for the commercial launch of a new product. The chair highlighted a solid revenue result, a broadened customer base, and the company's strategic positioning for continued growth in FY27.
Key Points
  • PolyNovo Limited introduced constant currency reporting to provide clearer insights into business performance by removing foreign exchange impacts.
  • The company's FY26 group revenue increased by 16.1% to AUD 150 million, with a larger increase of 20.3% in constant currency terms.
  • United States commercial sales reached AUD 102.1 million, showing a growth of 15.6% from the previous year.
  • Significant growth was observed in NovoSorb MTX commercial sales, which increased by 89.6%.
  • PolyNovo completed its new manufacturing facility with validation activities progressing as planned.
  • Insurance progress payments of AUD 3.5 million were received following a fire at the R&D Centre.
  • The company made substantial investments in its U.S. sales organization, with frontline personnel exceeding 100 people.
  • PolyNovo plans to launch NovoSorb® SynPath® commercially, focusing on outpatient opportunities.
  • The company's chair, Leon Hoare, noted strong FY26 revenue, broadening of the customer base, and anticipated growth into FY27.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.